SWOG S1823/CCTG GCC-01 secondary use of data Wednesday, March 18, 2026 SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours.Clinical stage I (CSI) testicular germ cell neoplasms (tGCN) represent the most frequent disease presentation and are highly curable. While active surveillance (AS) is increasingly favored as initial management, practice heterogeneity persists. The SWOG/CCTG S1823/GCC-001 trial is a prospective, non-interventional cohort study evaluating microRNA 371a-3p as a diagnostic biomarker in germ cell tumors. A pre-planned secondary analysis of this dataset to characterize real-world treatment patterns and baseline characteristics of CSI tGCN across North America. Coulombe AM, Ozgun G, Colby S, King J, Neuhouser ML, Zell JA, Arun B, Daneshmand S, Harzstark A, Arnold KB, Kollmannsberger CK, Nichols CR, Nappi L. SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours. ASCO Genitourinary Cancer Symposium. Journal of Clinical Oncology 44 [7_suppl], 622-622. 2026.https://ascopubs.org/doi/abs/10.1200/JCO.2026.44.7_suppl.622 It was a poster presentation at the ASCO Genitourinary Cancer Symposium, February 26-28, 2026 in San Francisco.
